Global Research Initiative for Patients Screening on MASH

Summary

GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD) and to raise awareness. The primary objective is to implement a transmural patient care pathway, in order to identify patients with MASLD and its progressive form metabolic dysfunction-associated steatohepatitis (MASH) in primary care centres and clinics in 10 European countries.

Conditions

• MASH
• MASLD
• MASH With Fibrosis
• Fibrosis, Liver
• Steatosis of Liver
• Type 2 Diabetes
• Obesity
• Metabolic Syndrome
• Arterial Hypertension

Sponsors & Collaborators

• UMC Utrecht

  collaborator OTHER

• Echosens

  collaborator INDUSTRY

• MIMETAS BV

  collaborator UNKNOWN

• Nordic Bioscience A/S

  collaborator INDUSTRY

• Elevate BV

  collaborator UNKNOWN

• Leiden University

  collaborator OTHER

• Amsterdam University Medical Center

  collaborator OTHER

• Andaluz Health Service

  collaborator OTHER_GOV

• National Research Council, Institute of Clinical Physiology, Italy

  collaborator OTHER

• Leiden University Medical Center

  collaborator OTHER

• Université Libre de Bruxelles

  collaborator OTHER

• University Hospital, Antwerp

  collaborator OTHER

• Catholic University of the Sacred Heart

  collaborator OTHER

• Medical Education Research And Innovation Center S.R.L.

  collaborator UNKNOWN

• EUROPEAN LIVER PATIENTS ASSOCIATION

  collaborator UNKNOWN

• Harokopio University

  collaborator OTHER

• General University Hospital, Prague

  collaborator OTHER

• Novo Nordisk A/S

  collaborator INDUSTRY

• Maastricht University

  collaborator OTHER

• Mercodia Aktiebolag

  collaborator UNKNOWN

• EXIT071 BV

  collaborator UNKNOWN

• European Atherosclerosis Society

  collaborator OTHER

• MetaDeq Limited

  collaborator UNKNOWN

• Associação para Investigação e Desenvolvimento da Faculdade de Medicina

  collaborator UNKNOWN

• Institute of Cardiometabolism and Nutrition, France

  collaborator OTHER

• University Hospital, Saarland

  collaborator OTHER

• Roche Pharma AG

  collaborator INDUSTRY

• Inventiva Pharma

  collaborator INDUSTRY

• Biocellvia

  collaborator UNKNOWN

• Franciscus Gasthuis & Vlietland (Hospital)

  collaborator OTHER

• Julius Clinical

  lead INDUSTRY

Principal Investigators

• Manuel Castro Cabezas, MD/PhD · Sint Franciscus Gasthuis

• Diederick E. Grobbee, MD/PhD/FESC · UMC Utrecht

• Oscar H. Franco, MD/PhD/FESC/FFPH · UMC Utrecht

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-06-30

Primary Completion

2031-03-31

Completion

2031-03-31

Countries

• Belgium
• Czechia
• France
• Germany
• Greece
• Italy
• Netherlands
• Portugal
• Romania
• Spain

Study Locations